Close Menu

NEW YORK – A long-standing development effort has come to fruition for Cepheid which this week debuted its 10-color molecular diagnostic testing technology in a new assay to help diagnose and profile extensively drug-resistant tuberculosis and select the best treatment.

Developed in collaboration with researchers at Rutgers University and with guidance and support from the Foundation for Innovative New Diagnostics, the test is now CE-IVD marked and the Danaher subsidiary said it expects to roll it out with assistance from FIND and the World Health Organization.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.